Quizartinib resistance issues and countermeasures

Acute myeloid leukemia (AML) is an extremely aggressive hematological malignancy. Its main feature is the abnormal proliferation of blast cells in the bone marrow, leading to the suppression of normal hematopoietic function. Among AML patients, FLT3-ITD mutation is one of the most common gene mutations. This mutation is closely related to a high risk of disease recurrence and poor prognosis. Quizartinib (Quizartinib), as a highly effective oral II typeFLT3 inhibitor, is widely used in the treatment of AML. Its mechanism is to selectively target and inhibit the activity of FLT3 kinase, thereby blocking the abnormal proliferation signals of leukemia cells.

However, the clinical application of quizartinib gradually exposed the problem of drug resistance. The development of drug resistance may originate from a variety of factors, such as mutations in the FLT3 gene itself, abnormal activation of the FLT3 signaling pathway, and abnormal expression of cell cycle proteins. These mechanisms lead to reduced sensitivity of leukemia cells to quizartinib, thus affecting the therapeutic effect.

Patients and doctors need to adopt multiple strategies to deal with resistance to quizartinib. First, combination therapy with multiple targeted drugs can be considered. By combining drugs with different mechanisms of action, the risk of developing resistance to a single drug can be reduced while overcoming existing drug resistance. Secondly, drug rotation therapy is also an effective strategy. When resistance to a certain targeted drug occurs, it can be switched to another targeted drug with a similar mechanism of action, thereby reactivating drug-resistant tumor cells. In addition, the application of immunotherapy provides new treatment ideas for drug resistance problems. For example, drugs such as immune checkpoints can enhance the immune system's ability to attack tumor cells.

In addition to the above strategies, it is also important to pay attention to the interactions between Quizartinib and other drugs, because some drugs may affect the metabolism and clearance of Quizartinib in the body, thereby changing its drug concentration and efficacy. When adjusting the treatment plan, doctors need to fully consider the patient's specific condition, genetic variation, liver and kidney function and other factors to formulate an individualized treatment plan.

In conclusion, resistance to quizartinib poses a major challenge in AML treatment. However, with reasonable treatment strategies, drug combinations, and ongoing disease monitoring and adjustment, patients may still be able to achieve effective treatment and control the progression of the disease. At the same time, future research should continue to explore new treatment methods to delay the occurrence of Quizartinib resistance and improve the treatment effect and survival rate of AML patients.

xa0

Reference: https://pmc.ncbi.nlm.nih.gov/articles/PMC7073218/#B60-ijms-21-01537